Literature DB >> 18634780

Clomipramine block of the hERG K+ channel: accessibility to F656 and Y652.

Su-Hyun Jo1, Hee-Kyung Hong, Seon Ha Chong, Kwang Hee Won, Sung Jun Jung, Han Choe.   

Abstract

Clomipramine is a tricyclic antidepressant for psychiatric disorders that can induce QT prolongation, which may lead to torsades de pointes. Since blockade of cardiac human ether-a-go-go-related gene (hERG) channels is an important cause of acquired long QT syndrome, we investigated the acute effects of clomipramine on hERG channels to determine the electrophysiological basis for its proarrhythmic potential. We examined the effects of clomipramine on the hERG channels expressed in Xenopus oocytes and HEK293 cells using two-microelectrode voltage-clamp and patch-clamp techniques. Clomipramine induced a concentration-dependent decrease in the current amplitude at the end of the voltage steps and hERG tail currents. The IC50 for clomipramine needed to block the hERG current in Xenopus oocytes decreased progressively relative to the degree of depolarization. The fractional electrical distance was estimated to be delta=0.83. The IC50 for the clomipramine-induced blockade of the hERG currents in HEK293 cells at 36 degrees C was 0.13 microM at +20 mV. Clomipramine affected the channels in the activated and inactivated states but not in the closed states. The clomipramine-induced blockade of hERG was found to be use-dependent, exhibiting a more rapid onset and a greater steady-state block at the higher frequencies of activation. The S6 domain mutations, Y652A and F656A partially attenuated (Y652A) or abolished (F656A) the hERG-current blockade. These results suggest that clomipramine is a blocker of the hERG channels, providing a molecular mechanism for the arrhythmogenic side effects during the clinical administration of clomipramine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18634780     DOI: 10.1016/j.ejphar.2008.06.094

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  Inhibitory actions of HERG currents by the immunosuppressant drug cyclosporin a.

Authors:  Seung Ho Lee; Sang June Hahn; Gyesik Min; Jimok Kim; Su-Hyun Jo; Han Choe; Bok Hee Choi
Journal:  Korean J Physiol Pharmacol       Date:  2011-10-31       Impact factor: 2.016

2.  Effects of lobeline, a nicotinic receptor ligand, on the cloned Kv1.5.

Authors:  Imju Jeong; Bok Hee Choi; Sang June Hahn
Journal:  Pflugers Arch       Date:  2010-08-24       Impact factor: 3.657

3.  Drug-specific risk of severe QT prolongation following acute drug overdose.

Authors:  Sharan L Campleman; Jeffery Brent; Anthony F Pizon; Joshua Shulman; Paul Wax; Alex F Manini
Journal:  Clin Toxicol (Phila)       Date:  2020-04-07       Impact factor: 4.467

4.  Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine.

Authors:  Sabrina Obers; Ingo Staudacher; Eckhard Ficker; Adrienne Dennis; Ronald Koschny; Hande Erdal; Ramona Bloehs; Jana Kisselbach; Christoph A Karle; Patrick A Schweizer; Hugo A Katus; Dierk Thomas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-13       Impact factor: 3.000

5.  A neonatal prolonged QT syndrome due to maternal use of oral tricyclic antidepressants.

Authors:  Naoya Fukushima; Kenji Nanao; Hiroyuki Fukushima; Akira Namera; Masaru Miura
Journal:  Eur J Pediatr       Date:  2016-04-12       Impact factor: 3.183

Review 6.  Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.

Authors:  Attila S Farkas; Stanley Nattel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

7.  Paroxetine suppresses recombinant human P2X7 responses.

Authors:  Phuong Dao-Ung; Kristen K Skarratt; Stephen J Fuller; Leanne Stokes
Journal:  Purinergic Signal       Date:  2015-09-05       Impact factor: 3.765

8.  Clinical use of antidepressant therapy and associated cardiovascular risk.

Authors:  W Stephen Waring
Journal:  Drug Healthc Patient Saf       Date:  2012-08-17

Review 9.  An Update on the Structure of hERG.

Authors:  Andrew Butler; Matthew V Helliwell; Yihong Zhang; Jules C Hancox; Christopher E Dempsey
Journal:  Front Pharmacol       Date:  2020-01-24       Impact factor: 5.810

10.  Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.

Authors:  Yihong Zhang; Charlotte K Colenso; Aziza El Harchi; Hongwei Cheng; Harry J Witchel; Chris E Dempsey; Jules C Hancox
Journal:  Biochem Pharmacol       Date:  2016-05-30       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.